ENDOXAN 50 mg

Open label, multicenter dose-escalation and cohort-expansion phase I/IIA trial of STC-1010, an immunotherapy, in patients with unresectable locally advanced or metastatic colorectal cancer (CRC) - BreAK CRC trial (BreAK for Brenus Anti-cancer).

REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma An open-label randomized phase II-III study

CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers

Randomized double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid - (RITUX-MMP)